Quoin Pharmaceuticals Ltd (QNRX) News

Tanh ?? next?

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Groundbreaking data from first whole body application of QRX003 underscores potential efficacy
Transformational improvement in disease state after just 2 weeks of treatment
Clear visual evidence of skin healing observed
Improvement has eliminated need for previously required medications
Patient is now experiencing zero nightly sleep disturbance for the first time
No adverse events reported from whole body treatment
ASHBURN, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. Dramatic improvement was observed in the patient’s disease state with clear visual evidence of skin healing observed after just two weeks of whole-body application of QRX003. No adverse events have been reported to date.

Both key clinical endpoints, Investigator’s Global Assessment (IGA) and Pruritus or itch, demonstrated highly significant clinical improvements from baseline after two weeks of treatment with QRX003 on patient’s whole body.

Table 1: Results for First Pediatric Patient Receiving QRX003 ‘Whole-Body’ Application

Endpoint* Baseline Two Week
Investigator Global Assessment 7 1-2
Pruritus 5 1
*Both IGA and Pruritus scores based on a 0-10 scale.

Furthermore, following treatment with QRX003, the patient has now discontinued previously required medications including all antihistamines, glucocorticoids and antivirals. Importantly, the patient has not needed treatment with any antibiotics since the whole-body application of QRX003 was initiated. In addition, the patient is now experiencing zero nightly sleep disturbances for the first time in her life. No adverse events have been reported to date.

Quoin CEO Dr. Michael Myers, said, “While cautioning upfront that this data is from just a single patient over a short period of time, these truly exciting and groundbreaking results provide a snapshot of the potential efficacy of QRX003 as a chronic whole-body treatment of Netherton Syndrome. After just two weeks of treatment, a transformational life change has occurred for this first patient to receive whole-body application of QRX003. At baseline, the Investigators Global Assessment, or IGA, for the patient’s skin was at 5 on a scale of 0-10. After two weeks of treatment with QRX003, the IGA was at 1, representing an almost complete elimination of the visual effects of the disease on the patient’s skin. In addition, her pruritus, which at baseline was described as “chronically debilitating itch” and a 7 on of a scale of 0-10, had significantly dropped to a “highly tolerable and non-intrusive” score of between 1 and 2 after only two weeks of treatment with QRX003. Even more encouraging is the fact that the patient has been able to discontinue ongoing treatment with a variety of previously required medications including antihistamines, antivirals, glucocorticoids and she has not needed any antibiotics since the initiation of dosing with QRX003. We believe that these results indicate that QRX003 is directly targeting the root cause of the disease and has the potential to provide NS patients with the opportunity to have lives essentially free from the ravages of this terrible disease. In addition, the patient is now, for the first time, experiencing zero nightly sleep disturbances, again providing additional evidence of the potential efficacy of QRX003. Finally, we are very pleased to report that no adverse events have been recorded after two weeks of twice-daily, whole-body application of QRX003. As we continue with our plans to expand this study to include additional pediatric subjects in other countries who would also receive whole body application of QRX003, we believe that the highly encouraging nature of the results generated to date for this patient could potentially bring hope and comfort to children and families whose lives are being so dramatically impacted by the consequences of this cruel disease.”

About Netherton Syndrome
Netherton Syndrome, a form of Ichthyosis, is a rare hereditary skin disorder caused by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Type 5) that leads to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma, and eczema. Patients often suffer from severe dehydration, chronic skin inflammation and stunted growth. Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.

QNRX................................................https://stockcharts.com/h-sc/ui?s=QNRX&p=W&b=5&g=0&id=p86431144783

QNRX...............................https://stockcharts.com/h-sc/ui?s=QNRX&p=W&b=5&g=0&id=p86431144783

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment.

Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome. Netherton Syndrome is a hereditary disorder affecting the skin, hair, and immune system, currently lacking an approved treatment or cure. Quoin is responsible for obtaining all FDA and other regulatory body approvals necessary to market the products in the US and other countries. Upon the successful completion of FDA or EU approval, Skinvisible is entitled to receive a milestone payment of $5 million and ongoing royalties from sales.

LICENSEE CLINICAL AND REGULATORY SUCCESS:

Skinvisible's licensee, Quoin Pharmaceuticals, Inc. (NASDAQ:QNRX) reported multiple positive developments for QRX003, which utilizes Skinvisible's Invisicare technology and its formulation for the rare skin disease: Netherton Syndrome:

Key Recent Developments:

FDA clearance for Netherton Syndrome "whole body" study at Northwestern University
Significant clinical improvements in both open label and pediatric studies including subject's disease classification improved from "severe" to "mild" after 6 weeks dosing
No adverse events or safety concerns reported to date from each of Quoin's ongoing clinical studies in Netherton Syndrome subjects
International expansion of studies to UK, Ireland, and Saudi Arabia
Netherton Syndrome product QRX003 with Invisicare delivery technology licensed in 60 countries
"We anticipate a significant milestone with our licensee potentially receiving the first FDA approval for a formulation using our Invisicare delivery technology," said Terry Howlett, President and CEO of Skinvisible. "This validates our strategy of developing innovative topical and transdermal therapeutics for other indications. As our licensee advances their clinical trials, we remain committed to supporting their efforts to bring this groundbreaking treatment to Netherton Syndrome patients worldwide."

Along with its ongoing research and development, Skinvisible continues to actively seek strategic partnerships with pharmaceutical and biotech companies to bring topical and transdermal Invisicare formulations to the market including the first transdermal obesity therapies and explore broader applications of its delivery platform with other small molecules.

For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please contact info@skinvisible.com.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section

Nice bump on results.91 +50%

At best your post is gibberish...

At worst it it is an ethnic slur...



chichi
in British English
('t?i??t?i? IPA Pronunciation Guide)
noun
Word forms: plural chichis
(formerly, in India)
a. a person of mixed British and Indian descent; Anglo-Indian
b. (as modifier)
a chichi accent
Also (less common): chee-chee
Collins English Dictionary. Copyright © HarperCollins Publishers
Word origin
C18: perhaps from Hindi chhi-chhi, literally: dirt, or perhaps imitative of their supposed singsong speech

There is no coherent translattion from the Chinese...

https://www.collinsdictionary.com/dictionary/english-chinese


https://www.collinsdictionary.com/dictionary/english/chee-chee

QNRX.............................https://stockcharts.com/h-sc/ui?s=QNRX&p=W&b=5&g=0&id=p86431144783

QNRX RUNNING HARD OFF THAT DIP

Vell that ended ... Maybe it'll be insider ship buys like the last time .... Otherwise zzzzzz zzzz zzzz

Catch the wave .. it's waving today

Hola Holmes. Chee Chee cheeee 

Playing hot potateo with the shorts? Chee Chee cheee

ZERO BORROW,300% fee!!

Load up earnings soon 11/6 and blow out numbers.  

Halt for upside then drops down. WTF

QNRX..................................https://stockcharts.com/h-sc/ui?s=QNRX&p=W&b=5&g=0&id=p86431144783

QNRX...DOLLAR RUNNER COMING IN

QNRX................................https://stockcharts.com/h-sc/ui?s=QNRX&p=W&b=5&g=0&id=p86431144783

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

UNYIELDING DUMPING

INCONTROVERTIBLE DUMPING

QNRX new 52 lo

Israeli stonk

Under $1….I wonder how that offering went lol

QNRX new 52 week low

bought 25,000 shares at 1.14 average

ready to DUMP after the CC tomorrow morning

QNRX new 52 lo

This is perhaps the best explanation of the share price action here I have ever heard

Dilution too little money chasing too many shares

I’m not sure how to read those filings. Did they get all they were looking for in that offering? Seems weird $1.60 a share and this is barely holding $1.20

QNRX 10Q due March 12

Israeli stonks are notorious for pump and dumps
A pump will begin two nanoseconds after the moomoo session opens for orders at 4am when it’s 11am in Tel Aviv
How long the pump lasts varies
Others may disagree with what I think is the usual senario for Israeli stonks
QNRX was done well before the 7am platforms open for orders
Sometimes the pump can continue after 7am when it’s 2pm in Tel Aviv
Most times, though put a for in it it’s done and the Tel Aviv players go out for dinner

I got some more 19’s. I don’t think an offering at 1.60 was issued for no reason. Insiders think this is going higher. Hit $2’s premarket.

I think we can see a nice move. We will see

Not bad. This can run.

I think it did

Did this hit $2 in premarket?

Wash trade bot running

Wash trade bot running

Thanks. Curious to see what happens. This ran to $6 recently

No, to create a wash trade run

Is that just to drop the stock?

Hong Kong, mainland Chinese, and Malaysian stonks are notorious for announcing an offering and then withdrawing it

What does that mean if they withdraw? It runs?

You just might
And then this Israeli stonk witndraws the offering and it sets off a wash trade bot rally

Offering closes tomorrow…. Wonder what happens to the price. We gonna see $1 and under?

QNRX new 52 week low

Bid sitting at .94 - I always bid 30-50% off offering price. Either it comes to me or I pass.

It would be crazy if this goes to .28 again after the split

Looks like they are going to do a rinse and repeat.